Cargando…
Loss of Intra-Islet CD20 Expression May Complicate Efficacy of B-Cell–Directed Type 1 Diabetes Therapies
OBJECTIVE: Consistent with studies in NOD mice, early clinical trials addressing whether depletion of B cells by the Rituximab CD20-specific antibody provides an effective means for type 1 diabetes reversal have produced promising results. However, to improve therapeutic efficacy, additional B-cell–...
Autores principales: | Serreze, David V., Chapman, Harold D., Niens, Marijke, Dunn, Robert, Kehry, Marilyn R., Driver, John P., Haller, Michael, Wasserfall, Clive, Atkinson, Mark A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3198088/ https://www.ncbi.nlm.nih.gov/pubmed/21926271 http://dx.doi.org/10.2337/db11-0705 |
Ejemplares similares
-
Prevention of “Humanized” Diabetogenic CD8 T-Cell Responses in HLA-Transgenic NOD Mice by a Multipeptide Coupled-Cell Approach
por: Niens, Marijke, et al.
Publicado: (2011) -
Interleukin-10(+) Regulatory B Cells Arise Within Antigen-Experienced CD40(+) B Cells to Maintain Tolerance to Islet Autoantigens
por: Kleffel, Sonja, et al.
Publicado: (2015) -
Idd Loci Synergize to Prolong Islet Allograft Survival Induced by Costimulation Blockade in NOD Mice
por: Mangada, Julie, et al.
Publicado: (2009) -
Acute Versus Progressive Onset of Diabetes in NOD Mice: Potential Implications for Therapeutic Interventions in Type 1 Diabetes
por: Mathews, Clayton E., et al.
Publicado: (2015) -
Idd9/11 Genetic Locus Regulates Diabetogenic Activity of CD4 T-Cells in Nonobese Diabetic (NOD) Mice
por: Chen, Yi-Guang, et al.
Publicado: (2008)